SYNEOS HEALTH INC (SYNH) Stock Fundamental Analysis
USA - NASDAQ:SYNH - US87166B1026 - Common Stock
42.98 USD
+0.01 (+0.02%)
42.97 USD
-0.01 (-0.02%)
Overall SYNH gets a fundamental rating of 4 out of 10. We evaluated SYNH against 58 industry peers in the Life Sciences Tools & Services industry. SYNH has a medium profitability rating, but doesn't score so well on its financial health evaluation. A decent growth rate in combination with a cheap valuation! Better keep an eye on SYNH.
1. Profitability
1.1 Basic Checks
In the past year SYNH was profitable.
SYNH had a positive operating cash flow in the past year.
In the past 5 years SYNH has always been profitable.
Each year in the past 5 years SYNH had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 0.88%, SYNH is doing good in the industry, outperforming 70.31% of the companies in the same industry.
Looking at the Return On Equity, with a value of 2.04%, SYNH is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
SYNH has a Return On Invested Capital of 4.23%. This is in the better half of the industry: SYNH outperforms 70.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SYNH is significantly below the industry average of 13.50%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROIC | 4.23% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
1.3 Margins
The Profit Margin of SYNH (1.31%) is better than 70.31% of its industry peers.
In the last couple of years the Profit Margin of SYNH has grown nicely.
Looking at the Operating Margin, with a value of 6.33%, SYNH is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
SYNH's Operating Margin has improved in the last couple of years.
The Gross Margin of SYNH (22.14%) is worse than 84.38% of its industry peers.
SYNH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% |
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SYNH is destroying value.
Compared to 1 year ago, SYNH has less shares outstanding
The debt/assets ratio for SYNH has been reduced compared to a year ago.
2.2 Solvency
SYNH has an Altman-Z score of 1.46. This is a bad value and indicates that SYNH is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SYNH (1.46) is comparable to the rest of the industry.
SYNH has a debt to FCF ratio of 16.71. This is a negative value and a sign of low solvency as SYNH would need 16.71 years to pay back of all of its debts.
SYNH has a better Debt to FCF ratio (16.71) than 65.63% of its industry peers.
SYNH has a Debt/Equity ratio of 0.77. This is a neutral value indicating SYNH is somewhat dependend on debt financing.
The Debt to Equity ratio of SYNH (0.77) is worse than 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Altman-Z | 1.46 |
ROIC/WACC0.39
WACC10.92%
2.3 Liquidity
SYNH has a Current Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.20, SYNH is not doing good in the industry: 93.75% of the companies in the same industry are doing better.
SYNH has a Quick Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
SYNH's Quick ratio of 1.20 is on the low side compared to the rest of the industry. SYNH is outperformed by 82.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
SYNH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.79%.
The Earnings Per Share has been growing by 13.74% on average over the past years. This is quite good.
The Revenue has been growing slightly by 0.01% in the past year.
Measured over the past years, SYNH shows a quite strong growth in Revenue. The Revenue has been growing by 15.08% on average per year.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
3.2 Future
The Earnings Per Share is expected to grow by 3.17% on average over the next years.
Based on estimates for the next years, SYNH will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SYNH is valuated reasonably with a Price/Earnings ratio of 11.37.
SYNH's Price/Earnings ratio is rather cheap when compared to the industry. SYNH is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. SYNH is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 10.48, the valuation of SYNH can be described as very reasonable.
100.00% of the companies in the same industry are more expensive than SYNH, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.59. SYNH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SYNH is valued cheaply inside the industry as 95.31% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SYNH is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.53 | ||
| EV/EBITDA | 12.05 |
4.3 Compensation for Growth
The decent profitability rating of SYNH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
5. Dividend
5.1 Amount
No dividends for SYNH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.98
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)5.42B
Net Income(TTM)71.22M
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 | ||
| P/S | 0.82 | ||
| P/FCF | 27.53 | ||
| P/OCF | 17.62 | ||
| P/B | 1.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.05 |
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROCE | 5.32% | ||
| ROIC | 4.23% | ||
| ROICexc | 4.29% | ||
| ROICexgc | 32.26% | ||
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% | ||
| FCFM | 2.99% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexgc growth 3Y-8.19%
ROICexgc growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Debt/EBITDA | 4.56 | ||
| Cap/Depr | 37.2% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 43.05% | ||
| Profit Quality | 227.34% | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z | 1.46 |
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%
SYNEOS HEALTH INC / SYNH FAQ
What is the ChartMill fundamental rating of SYNEOS HEALTH INC (SYNH) stock?
ChartMill assigns a fundamental rating of 5 / 10 to SYNH.
Can you provide the valuation status for SYNEOS HEALTH INC?
ChartMill assigns a valuation rating of 7 / 10 to SYNEOS HEALTH INC (SYNH). This can be considered as Undervalued.
Can you provide the profitability details for SYNEOS HEALTH INC?
SYNEOS HEALTH INC (SYNH) has a profitability rating of 6 / 10.
What is the valuation of SYNEOS HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SYNEOS HEALTH INC (SYNH) is 11.37 and the Price/Book (PB) ratio is 1.28.
What is the earnings growth outlook for SYNEOS HEALTH INC?
The Earnings per Share (EPS) of SYNEOS HEALTH INC (SYNH) is expected to decline by -25.43% in the next year.